🎉 M&A multiples are live!
Check it out!

Intensity Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Intensity Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Intensity Therapeutics Overview

About Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.


Founded

2012

HQ

United States of America
Employees

16

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$25.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Intensity Therapeutics Financials

Intensity Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Intensity Therapeutics achieved revenue of n/a and an EBITDA of -$16.3M.

Intensity Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Intensity Therapeutics valuation multiples based on analyst estimates

Intensity Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$10.2M -$16.3M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$7.6M -$10.5M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $3.0M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Intensity Therapeutics Stock Performance

As of April 15, 2025, Intensity Therapeutics's stock price is $2.

Intensity Therapeutics has current market cap of $28.4M, and EV of $25.9M.

See Intensity Therapeutics trading valuation data

Intensity Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$25.9M $28.4M XXX XXX XXX XXX $-1.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Intensity Therapeutics Valuation Multiples

As of April 15, 2025, Intensity Therapeutics has market cap of $28.4M and EV of $25.9M.

Intensity Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Intensity Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Intensity Therapeutics and 10K+ public comps

Intensity Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $25.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.6x XXX XXX XXX
P/E -1.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Intensity Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Intensity Therapeutics Valuation Multiples

Intensity Therapeutics's NTM/LTM revenue growth is n/a

Intensity Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Intensity Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Intensity Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Intensity Therapeutics and other 10K+ public comps

Intensity Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 59% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Intensity Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Intensity Therapeutics M&A and Investment Activity

Intensity Therapeutics acquired  XXX companies to date.

Last acquisition by Intensity Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Intensity Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Intensity Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Intensity Therapeutics

When was Intensity Therapeutics founded? Intensity Therapeutics was founded in 2012.
Where is Intensity Therapeutics headquartered? Intensity Therapeutics is headquartered in United States of America.
How many employees does Intensity Therapeutics have? As of today, Intensity Therapeutics has 16 employees.
Who is the CEO of Intensity Therapeutics? Intensity Therapeutics's CEO is Mr. Lewis H. Bender.
Is Intensity Therapeutics publicy listed? Yes, Intensity Therapeutics is a public company listed on NAS.
What is the stock symbol of Intensity Therapeutics? Intensity Therapeutics trades under INTS ticker.
When did Intensity Therapeutics go public? Intensity Therapeutics went public in 2023.
Who are competitors of Intensity Therapeutics? Similar companies to Intensity Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Intensity Therapeutics? Intensity Therapeutics's current market cap is $28.4M
Is Intensity Therapeutics profitable? Yes, Intensity Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.